Friday, July 10, 2026

pharma · CACNA1A Disorders · Niemann-Pick disease type C

IntraBio

Intrabio Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include CACNA1A Disorders, Niemann-Pick disease type C, Ataxia Telangiectasia. NovaPharmaNews links 3 clinical program(s), 0

Austin, USA HQ
44 Employees
EMA registrant Type
Company details
Status
Public
HQ
Austin, USA
Employees
44
Programs
3
Drugs
3
Patents
0
Clinical program

Granules for oral suspension, N-Acetyl-L-Leucine

Phase 3 · small molecule · Niemann-Pick disease type C

Granules for oral suspension, N-Acetyl-L-Leucine for Niemann-Pick disease type C is a Phase 3 program (small_molecule) at Intrabio Ireland Limited with 1 ClinicalTrials.gov record(s).

← All Intrabio Ireland Limited projects Phase 3 small molecule active

Internal code IB1001-301

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Intrabio Ireland Limited
Phase
Phase 3
Modality
small_molecule
Indication
Niemann-Pick disease type C
Status
active
Trials
1